Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Timothy CoughlinDirector | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 06/12 | 06/16 | 10,000 sh | $50.07 | $500,700 | −15.1% |
Roy D. BaynesDirector | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 06/12 | 06/16 | 4,500 sh | $50.00 | $225,000 | −9.8% |
Timothy CoughlinDirector | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/15 | 05/19 | 3,250 sh | $43.49 | $141,342.5 | −5.9% |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/04–05/06 | 05/06 | 24,250 sh3 trades | $45.06avg. | $1,092,657.3 | −18.7% | |
Rote William E.Chief Research Officer | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/06 | 05/06 | 2,763 sh | $43.95 | $121,433.85 | −2.3% |
Dube Eric M.CEO | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/06 | 05/06 | 22,500 sh | $43.95 | $988,875 | −4.9% |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/04–05/06 | 05/06 | 22,485 sh3 trades | $45.15avg. | $1,015,085.55 | −16.6% | |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/05–05/06 | 05/06 | 2,491 sh2 trades | $46.31avg. | $115,368.15 | −2.1% | |
Roy D. BaynesDirector | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/05 | 05/06 | 4,500 sh | $46.65 | $209,925 | −10.7% |
Peter HeermaChief Commercial Officer | Travere TherapeuticsTVTX | Open-market sale | 05/05 | 05/06 | 2,174 sh | $46.65 | $101,417.1 | −1.5% |
Jeffrey A. MecklerDirector | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/04 | 05/06 | 8,000 sh | $45.00 | $360,000 | −8.4% |
Roy D. BaynesDirector | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 05/01 | 05/04 | 9,750 sh | $44.22 | $431,145 | −20.6% |
Rote William E.Chief Research Officer | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/22 | 04/23 | 9,100 sh | $39.09 | $355,719 | −7.4% |
Gary A. LyonsDirector | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/14 | 04/16 | 8,000 sh | $41.07 | $328,560 | −12.2% |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/14 | 04/16 | 32,750 sh2 trades | $41.29avg. | $1,352,130 | −46.6% | |
Sandra CalvinSVP, Chief Accounting Officer | Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/14 | 04/16 | 21,977 sh | $41.07 | $902,595.39 | −34.2% |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/14–04/15 | 04/15 | 51,500 sh4 trades | $41.29avg. | $2,126,460.34 | −32.9% | |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/15 | 04/15 | 64,000 sh3 trades | $41.09avg. | $2,629,975.1 | −12.9% | |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/14–04/15 | 04/15 | 8,233 sh2 trades | $42.01avg. | $345,901.93 | −6.9% | |
Travere TherapeuticsTVTX | Open-market sale10b5-1 plan | 04/13–04/15 | 04/15 | 8,327 sh4 trades | $41.91avg. | $348,982.69 | −6.6% |